瑞银下调莫德纳目标价至34美元
Ge Long Hui A P P·2026-01-09 08:28

Group 1 - UBS has lowered Moderna's target price from $40 to $34, indicating a decrease in expected valuation [1] - The rating for Moderna has been downgraded from "Buy" to "Neutral," reflecting a more cautious outlook on the company's performance [1]